Patent details

EP3370756 Title: COMBINATION OF CANRENOATE AND EXENATIDE

Basic Information

Publication number:
EP3370756
PCT Application Number:
IB2016001582
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP168021327
PCT Publication Number:
WO2017077378
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
COMBINATION OF CANRENOATE AND EXENATIDE
French Title of Invention:
COMBINAISON DE CANRÉNOATE ET EXENATIDE
German Title of Invention:
KOMBINATION VON CANRENOATE UND EXENATIDE
SPC Number:

Dates

Filing date:
04/11/2016
Grant date:
08/04/2020
EP Publication Date:
12/09/2018
PCT Publication Date:
11/05/2017
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
08/04/2020
EP B1 Publication Date:
08/04/2020
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
04/11/2036
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
01/04/2020
 
 

Name:
Genesis Pharma SA
Address:
270 Kifissias Avenue, 15232 Athens, Greece (GR)

Agent

Name:
ARONOVA S.A.
From:
28/05/2020
Address:
PO Box 327, L-4004, ESCH-SUR-ALZETTE, Luxembourg (LU)
To:

Inventor

Name:
VOGIATZIS, George
Address:
Greece (GR)

Priority

Priority Number:
20150100486
Priority Date:
06/11/2015
Priority Country:
Greece (GR)

Classification

IPC classification:
A61K 38/13; A61K 38/26; A61P 9/10;

Publication

European Patent Bulletin

Issue number:
202015
Publication date:
08/04/2020
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
01/12/2025
Annual Fee Number:
10
Annual Fee Amount:
131 Euro
Expected Payer:
Last Annual Fee Payment Date:
18/11/2024
Last Annual Fee Paid Number:
9
Last Annual Fee Paid Amount:
115 Euro
Payer:
CLARIVATE IP SERVICES LIMITED
Filing date Document type Number of pages
28/05/2020 Power Of Attorney 1
28/05/2020 Outgoing Correspondence 1